Phase II trial of methyl-G (methylglyoxal bis-guanylhydrazone) in patients with metastatic renal cell carcinoma.

J. Z. Fuks, D. A. Van Echo, Joseph Aisner, E. P. Mitchell, P. V. Woolley, P. H. Wiernik

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Fourteen patients with metastatic renal cell carcinoma received methyl-G weekly at a starting dose of 600 mg/m2 (five patients) and 500 mg/m2 (nine patients) intravenously. All 14 patients are evaluable for response and toxicity. No antitumor responses were observed. Six patients achieved stabilization of disease for 8 to 42 weeks. Toxicity was nonhematologic and included nausea or vomiting (35%), fever with shaking chills (28%), diarrhea (21%), myalgia (63%), paresthesia (49%), and bilateral foot drop (7%). Methyl-G does not appear to have activity against renal cell carcinoma.

Original languageEnglish (US)
Pages (from-to)411-414
Number of pages4
JournalCancer clinical trials
Volume4
Issue number4
StatePublished - Dec 1 1981

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'Phase II trial of methyl-G (methylglyoxal bis-guanylhydrazone) in patients with metastatic renal cell carcinoma.'. Together they form a unique fingerprint.

Cite this